PharmaPoint: Macular Edema and Macular Degeneration - Global Drug Forecast and Market Analysis to 2023

  • Pages: 450
  • Published: October 2014
  • Format:
  • Report Code: GDHC111PIDR
  • Add to Saved List

Invite Credit Card Holder to pay

Requester Details

Credit Card Holder Details

Company Details

Message to be included

Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.

Scope

Overview of ME and AMD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.

Annualized ME and AMD market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.

Key topics covered include market characterization, unmet needs, R&D and clinical trials assessment, late stage clinical trial analysis and implications for the ME and AMD therapeutics markets.

Pipeline analysis: focus on the seven late-stage pipeline ME and AMD drugs discussing emerging trends as well as overview of earlier phase drugs.

Analysis of the current and future market competition in the global ME and AMD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Key Highlights

The ME market has been dominated by anti-VEGF drugs Lucentis and Avastin for many years, however, rival drug Eylea has recently gained approval for ME indications across the 7MM. How will this impact the positions that Lucentis and Avastin hold in this market? How will this change over the forecast period, and which drug will covet the leading position in 2023?

The current late stage AMD pipeline is varied, with first-in-class drugs in development for both dry AMD and wet AMD. Which of these will have the biggest impact on the AMD market? What strategies are developers undertaking to penetrate the wet AMD market? Will the novel dry AMD drugs fulfil the huge unmet need for this retinal disease?

Population aging is occurring in almost all countries worldwide, particularly in the 7MM. This is expected to have a significant impact on the prevalence of age-related diseases such as AMD and conditions causing ME. How will epidemiological changes impact the growth of the future ME and AMD markets?

Companies mentioned

Acucela

Alimera Sciences

Allergan

Ampio Pharmaceuticals

Bayer

Genentech

Novartis

Ohr Pharmaceuticals

Ophthotech

Otsuka

pSivida

Regeneron

Roche

Santen

Valeant

Acucela

Alimera Sciences

Allergan

Ampio Pharmaceuticals

Bayer

Genentech

Novartis

Ohr Pharmaceuticals

Ophthotech

Otsuka

pSivida

Regeneron

Roche

Santen

Valeant

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Related Reports

3Disease Overview

3.1Macular Degeneration Overview

3.1.1Etiology and ...

1Table of Contents

1.1List of Tables

1.2List of Figures

2Introduction

2.1Related Reports

3Disease Overview

3.1Macular Degeneration Overview

3.1.1Etiology and Pathophysiology

3.1.2Classification

3.1.3Symptoms and Diagnosis

3.2Macular Edema Overview

3.2.1Etiology and Pathophysiology

3.2.2Classification

3.2.3Symptoms and Diagnosis

4Epidemiology - Macular Edema

4.1Disease Background

4.2Risk Factors and Comorbidities

4.3Global Trends

4.3.1US

4.3.25EU

4.3.3Japan

4.4Forecast Methodology

4.4.1Sources Used

4.4.2Sources Not Used

4.4.3Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetes

4.4.4Forecast Assumptions and Methods — Diagnosed Prevalent Cases of Diabetic Retinopathy

4.4.5Forecast Assumptions and Methods – Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.4.6Forecast Assumptions and Methods – Total Prevalent Cases of ME following BRVO and CRVO

4.5Epidemiological Forecast for Macular Edema (2013–2023)

4.5.1Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.2Age-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.3Sex-Specific Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population

4.5.4Total Prevalent Cases of ME Following BRVO

4.5.5Age-Specific Total Prevalent Cases of ME Following BRVO

4.5.6Sex-Specific Total Prevalent Cases of ME following BRVO

4.5.7Total Prevalent Cases of ME Following CRVO

4.5.8Age-Specific Total Prevalent Cases of ME Following CRVO

4.5.9Sex-Specific Total Prevalent Cases of ME Following CRVO

4.6Discussion

4.6.1Epidemiological Forecast Insight

4.6.2Limitations of the Analysis

4.6.3Strengths of the Analysis

5Epidemiology - Age-Related Macular Degeneration

5.1Disease Background

5.2Risk Factors and Comorbidities

5.3Global Trends

5.3.1US

5.3.25EU

5.3.3Japan

5.4Forecast Methodology

5.4.1Sources Used

5.4.2Forecast Assumptions and Methods

5.5Epidemiological Forecast for AMD (2013–2023)

5.5.1Total Prevalent Cases of AMD

5.5.2Age-Specific Total Prevalent Cases of AMD

5.5.3Sex-Specific Total Prevalent Cases of AMD

5.5.4Age-Standardized Total Prevalence of AMD

5.5.5Total Prevalent Cases of AMD by Stage

5.5.6Total Prevalent Cases of Late AMD by Subtype

5.6Discussion

5.6.1Epidemiological Forecast Insight

5.6.2Limitations of the Analysis

5.6.3Strengths of the Analysis

6Disease Management

6.1Diagnosis and Treatment Overview

6.1.1Macular Edema Diagnosis

6.1.2Macular Degeneration Diagnosis

6.1.3Treatment Guidelines and Leading Prescribed Drugs

6.1.4Clinical Practice

6.2US

6.3France

6.4Germany

6.5Italy

6.6Spain

6.7UK

6.8Japan

7Competitive Assessment

7.1Overview

7.2Product Profiles – Major Brands

7.2.1Lucentis (ranibizumab)

7.2.2Eylea (aflibercept)

7.2.3Avastin (bevacizumab)

7.2.4Macugen (pegaptanib sodium)

7.2.5Visudyne (verteporfin)

7.2.6Corticosteroid Implants

8Unmet Need and Opportunity

8.1Overview

8.2Treatment for Dry AMD

8.2.1Unmet Need

8.2.2Gap Analysis

8.2.3Opportunity

8.3Longer-Acting Anti-VEGF Drug Therapy

8.3.1Unmet Need

8.3.2Gap Analysis

8.3.3Opportunity

8.4Increased Efficacy of Anti-VEGF Therapy for wAMD

8.4.1Unmet Need

8.4.2Gap Analysis

8.4.3Opportunity

8.5Less Invasive Drug Formulations

8.5.1Unmet Need

8.5.2Gap Analysis

8.5.3Opportunity

8.6Awareness and Earlier Patient Diagnosis

8.6.1Unmet Need

8.6.2Gap Analysis

8.6.3Opportunity

8.7Home Monitoring of AMD Progression

8.7.1Unmet Need

8.7.2Gap Analysis

8.7.3Opportunity

9Pipeline Assessment

9.1Overview

9.2Clinical Trial Mapping

9.3Promising Drugs in Clinical Development

9.3.1Abicipar pegol

9.3.2Fovista

9.3.3Squalamine

9.3.4Lampalizumab

9.3.5Emixustat

9.3.6Optina

9.3.7DE-102

9.4Promising Drugs in Early-Stage Development

9.4.1Complement Inhibitors

9.5Other Drugs in Development

9.6Biosimilars

10Current and Future Players

10.1Overview

10.2Trends in Corporate Strategy

10.3Company Profiles

10.3.1Roche/Genentech

10.3.2Novartis

10.3.3Regeneron

10.3.4Bayer

10.3.5Valeant

10.3.6Allergan

10.3.7Alimera Sciences

10.3.8Ampio Pharmaceuticals

10.3.9Ophthotech

10.3.10Acucela

10.3.11Ohr Pharmaceuticals

11Market Outlook

11.1Global Markets

11.1.1Forecast

11.1.2Drivers and Barriers – Global Issues

11.2US

11.2.1Forecast

11.2.2Key Events

11.2.3Drivers and Barriers

11.3France

11.3.1Forecast

11.3.2Key Events

11.3.3Drivers and Barriers

11.4Germany

11.4.1Forecast

11.4.2Key Events

11.4.3Drivers and Barriers

11.5Italy

11.5.1Forecast

11.5.2Key Events

11.5.3Drivers and Barriers

11.6Spain

11.6.1Forecast

11.6.2Key Events

11.6.3Drivers and Barriers

11.7UK

11.7.1Forecast

11.7.2Key Events

11.7.3Drivers and Barriers

11.8Japan

11.8.1Forecast

11.8.2Key Events

11.8.3Drivers and Barriers

12Appendix

12.1Bibliography

12.2Abbreviations

12.3Methodology

12.4Forecasting Methodology

12.4.1Diagnosed ME and AMD Patients

12.4.2Percentage of Drug-Treated Patients

12.4.3Drugs Included in Each Therapeutic Class

12.4.4Launch and Patent Expiry Dates

12.4.5General Pricing Assumptions

12.4.6Individual Drug Assumptions

12.4.7Pricing of Pipeline Agents

12.5Primary Research – KOLs Interviewed for this Report

12.6Primary Research – High-Prescribers Survey

12.7About the Authors

12.7.1Analyst

12.7.2Therapy Area Director

12.7.3Epidemiologist

12.7.4Global Head of Healthcare

12.8About GlobalData

12.9Disclaimer

List of tables

Table 1: ARM System Classification of AMD

Table 2: Symptoms of AMD

Table 3: Risk Factors for DME

Table 4: Comorbidities for DME

Table 5 ...

Table 1: ARM System Classification of AMD

Table 2: Symptoms of AMD

Table 3: Risk Factors for DME

Table 4: Comorbidities for DME

Table 5: 7MM, Sources of Diagnosed Prevalence of DME in the Diagnosed Diabetic Retinopathy Population

Table 6: 7MM, Sources of Total Prevalence of ME following BRVO and CRVO

Table 7: 7MM, Sources Not Used in Epidemiological Analysis of DME

Table 8: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages =20 Years, Both Sexes, N, 2013–2023

Table 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, (Row %), 2013

Table 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages =20 Years, N (Row %), 2013

Table 11: 7MM, Total Prevalent Cases of ME Following BRVO, Ages =20 Years, Both Sexes, N, 2013–2023

Table 12: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, (Row %), 2013

Table 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages =20 Years, N (Row %), 2013

Table 14: 7MM, Total Prevalent Cases of ME Following CRVO, Ages =20 Years, Both Sexes, N, 2013–2023

Table 15: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, (Row %), 2013

Table 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages =20 Years, N (Row %), 2013

Table 17: Risk Factors and Comorbidities for AMD

Table 18: Diagnostic Criteria for AMD

Table 19: 7MM, Sources of AMD Prevalence Data

Table 20: 7MM, Total Prevalent Cases of AMD, Ages =50 Years, Both Sexes, N, 2013–2023

Table 21: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, (Row %), 2013

Table 22: 7MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N (Row %), 2013

Table 23: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age =50 Years, N (Row %), 2013

Table 24: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age =50 Years, N (Row %), 2013

Table 25: National and International Treatment Guidelines for ME and AMD

Table 26: Most Prescribed Drugs for ME and AMD in the Global Markets, 2013

Table 27: ME and AMD Disease Management – US

Table 28: ME and AMD Disease Management – France

Table 29: ME and AMD Disease Management – Germany

Table 30: ME and AMD Disease Management – Italy

Table 31: ME and AMD Disease Management – Spain

Table 32: ME and AMD Disease Management – UK

Table 33: ME and AMD Disease Management – Japan

Table 34: Leading Treatments for ME and AMD, 2014

Table 35: Product Profile – Lucentis

Table 36: Lucentis SWOT Analysis, 2014

Table 37: Global Sales Forecast ($m) for Lucentis, 2013–2023

Table 38: Approval Dates for Eylea

Table 39: Product Profile – Eylea

Table 40: Eylea — Common Adverse Reactions

Table 41: Eylea SWOT Analysis, 2014

Table 42: Global Sales Forecast ($m) for Eylea, 2013–2023

Table 43: Product Profile – Avastin

Table 44: Avastin SWOT Analysis, 2014

Table 45: Global Sales Forecast ($m) for Avastin, 2013–2023

Table 46: Product Profile – Macugen

Table 47: Product Profile – Visudyne

Table 48: Visudyne SWOT Analysis, 2014

Table 49: Global Sales Forecast ($m) for Visudyne, 2013–2023

Table 50: Product Profile – Ozurdex

Table 51: Product Profile – Iluvien

Table 52: Corticosteroid IVT Implants SWOT Analysis, 2014

Table 53: Global Sales Forecast ($m) for Ozurdex, 2013–2023

Table 54: Global Sales Forecast ($m) for Iluvien, 2013–2023

Table 55: Unmet Needs and Opportunities in ME and AMD

Table 56: Promising Drugs in Clinical Development for ME and AMD

Table 57: Comparison of Drugs in Development for ME and AMD, 2014

Table 58: Product Profile – Abicipar pegol

Table 59: SWOT Analysis – Abicipar pegol, 2014

Table 60: Global Sales Forecast ($m) for Abicipar Pegol, 2013–2023

Table 61: Product Profile – Fovista

Table 62: SWOT Analysis – Fovista, 2014

Table 63: Global Sales Forecast ($m) for Fovista, 2013–2023

Table 64: Product Profile – Squalamine

Table 65: SWOT Analysis – Squalamine, 2014

Table 66: Global Sales Forecast ($m) for squalamine, 2013–2023

Table 67: Product Profile – Lampalizumab

Table 68: SWOT Analysis – Lampalizumab, 2014

Table 69: Global Sales Forecast ($m) for lampalizumab, 2013–2023

Table 70: Product Profile – Emixustat

Table 71: SWOT Analysis – Emixustat, 2014

Table 72: Global Sales Forecast ($m) for emixustat, 2013–2023

Table 73: Product Profile – Optina

Table 74: SWOT Analysis – Optina, 2014

Table 75: Global Sales Forecast ($m) for Optina, 2013–2023

Table 76: Product Profile – DE-102

Table 77: DE-102 SWOT Analysis, 2014

Table 78: Global Sales Forecast ($m) for DE-102, 2013–2023

Table 79: Early-Stage Drugs in Clinical Development for ME and AMD, 2014

Table 80: Key Companies in the ME and AMD Markets in the 7MM, 2014

Table 81: Roche/Genentech’s ME and AMD Portfolio Assessment, 2014

Table 82: Novartis’ ME and AMD Portfolio Assessment, 2014

Table 83: Regeneron’s ME and AMD Portfolio Assessment, 2014

Table 84: Bayer’s ME and AMD Portfolio Assessment, 2014

Table 85: Valeant’s AMD Portfolio Assessment, 2014

Table 86: Allergan’s ME and AMD Portfolio Assessment, 2014

Table 87: Alimera Sciences’ ME Portfolio Assessment, 2014

Table 88: Ampio’s ME Portfolio Assessment, 2014

Table 89: Ophthotech’s AMD Portfolio Assessment, 2014

Table 90: Acucela’s AMD Portfolio Assessment, 2014

Table 91: Ohr Pharmaceutical’s AMD Portfolio Assessment, 2014

Table 92: Global Sales Forecast ($m) for ME, 2013–2023

Table 93: Global Sales Forecast ($m) for AMD, 2013–2023

Table 94: ME and AMD Markets – Drivers and Barriers, 2013–2023

Table 95: Sales Forecast ($m) for ME in the U, 2013–2023

Table 96: Sales Forecast ($m) for AMD in the United States, 2013–2023

Table 97: Key Events Impacting Sales for ME and AMD in the US, 2013–2023

Table 98: ME and AMD Markets – Drivers and Barriers in the US, 2013–2023

Table 99: Sales Forecast ($m) for ME in France, 2013–2023

Table 100: Sales Forecast ($m) for AMD in France, 2013–2023

Table 101: Key Events Impacting Sales for ME and AMD in France, 2013–2023

Table 102: ME and AMD Markets – Drivers and Barriers in France, 2013–2023

Table 103: Sales Forecast ($m) for ME in Germany, 2013–2023

Table 104: Sales Forecast ($m) for AMD in Germany, 2013–2023

Table 105: Key Events Impacting Sales for ME and AMD in Germany, 2013–2023

Table 106: ME and AMD Markets – Drivers and Barriers in Germany, 2013–2023

Table 107: Sales Forecast ($m) for ME in Italy, 2013–2023

Table 108: Sales Forecast ($m) for AMD in Italy, 2013–2023

Table 109: Key Events Impacting Sales for MME and AMD in Italy, 2013–2023

Table 110: ME and AMD Markets – Drivers and Barriers in Italy, 2013–2023

Table 111: Sales Forecast ($m) for ME in Spain, 2013–2023

Table 112: Sales Forecast ($m) for AMD in Spain, 2013–2023

Table 113: Key Events Impacting Sales for ME and AMD in Spain, 2013–2023

Table 114: ME and AMD Markets – Drivers and Barriers in Spain, 2013–2023

Table 115: Sales Forecast ($m) for ME in the UK, 2013–2023

Table 116: Sales Forecast ($m) for AMD in the UK, 2013–2023

Table 117: Key Events Impacting Sales for ME and AMD in the UK, 2013–2023

Table 118: ME and AMD Markets – Drivers and Barriers in the UK, 2013–2023

Table 119: Sales Forecast ($m) for ME in Japan, 2013–2023

Table 120: Sales Forecast ($m) for AMD in Japan, 2013–2023

Table 121: Key Events Impacting Sales for ME and AMD in Japan, 2013–2023

Table 122: ME and AMD Markets – Drivers and Barriers in Japan, 2013–2023

Table 123: Key Launch Dates

Table 124: Key Patent Expiries

Table 125: Surveyed High-Prescribing Physicians (Non-KOLs), by Country

List of figures

Figure 1: Anatomy of the Eye and Macula

Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD

Figure 3: Color Fundus ...

Figure 1: Anatomy of the Eye and Macula

Figure 2: Amsler Grid viewed by Patient with Normal Vision and with wAMD

Figure 3: Color Fundus Photographs of Dry and Wet AMD

Figure 4: FAF Imaging of GA

Figure 5: Imaging of wAMD

Figure 6: CMT in DME

Figure 7: RVOs (BRVO and CRVO) on an FA

Figure 8: Increased CRT in ME-RVO

Figure 9: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, Ages =20 Years, Both Sexes, N, 2013–2023

Figure 10: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Age, Both Sexes, N, 2013

Figure 11: 7MM, Diagnosed Prevalent Cases of DME in the Diagnosed Diabetic Retinopathy Population, by Sex, Ages =20 Years, N, 2013

Figure 12: 7MM, Total Prevalent Cases of ME Following BRVO, Ages =20 Years, Both Sexes, N, 2013–2023

Figure 13: 7MM, Total Prevalent Cases of ME Following BRVO, by Age, Both Sexes, N, 2013

Figure 14: 7MM, Total Prevalent Cases of ME Following BRVO, by Sex, Ages =20 Years, N, 2013

Figure 15: 7MM, Total Prevalent Cases of ME Following CRVO, Ages =20 Years, Both Sexes, N, 2013–2023

Figure 16: 7MM, Total Prevalent Cases of ME Following CRVO, by Age, Both Sexes, N, 2013

Figure 17: 7MM, Total Prevalent Cases of ME Following CRVO, by Sex, Ages =20 Years, N, 2013

Figure 18: 7MM, Total Prevalent Cases of AMD, Ages =50 Years, Both Sexes, N, 2013–2023

Figure 19: 7MM, Total Prevalent Cases of AMD, by Age, Both Sexes, N, 2013

Figure 20: 7MM, Total Prevalent Cases of AMD, by Sex, Ages =50 Years, N, 2013

Figure 21: 7MM, Age-Standardized Total Prevalence (%) of AMD, Age =50 Years, by Sex, 2013

Figure 22: 7MM, Total Prevalent Cases of AMD by Stage, Both Sexes, Age =50 Years, N, 2013

Figure 23: 7MM, Total Prevalent Cases of Late AMD by Subtype, Both Sexes, Age =50 Years, N, 2013

Figure 24: ME Clinical Treatment Flowchart

Figure 25: AMD Clinical Treatment Flowchart

Figure 26: Eylea’s Clinical Development in DME and ME-BRVO

Figure 27: Iluvien’s and Ozurdex’s Clinical Development in wAMD, dAMD, and DME

Figure 28: ME and AMD therapeutics – Number of Phase II and III Clinical Trials in Each Indication in the 7MM

Figure 29: Competitive Assessment of Late-Stage Pipeline Agents in ME and AMD, 2013–2023

Figure 30: Abicipar Pegol’s Clinical Development in wAMD and DME

Figure 31: Clinical and Commercial Positioning of abicipar pegol

Figure 32: Fovista’s Clinical Development in wAMD

Figure 33: Clinical and Commercial Positioning of Fovista

Figure 34: Squalamine’s Clinical Development in wAMD and DME

Figure 35: Clinical and Commercial Positioning of squalamine

Figure 36: Lampalizumab’s Development in wAMD

Figure 37: Clinical and Commercial Positioning of lampalizumab

Figure 38: Emixustat Clinical Development in dAMD

Figure 39: Clinical and Commercial Positioning of emixustat

Figure 40: Optina’s Clinical Development in DME

Figure 41: Clinical and Commercial Positioning of Optina

Figure 42: DE-102’s Clinical Development in DME and ME-BRVO

Figure 43: Clinical and Commercial Positioning of DE-102

Figure 44: Global Sales of Branded Products for ME and AMD by Company, 2013–2023

Figure 45: Company Portfolio Gap Analysis in ME and AMD, 2013–2023

Figure 46: Roche/Genentech’s SWOT Analysis in ME and AMD, 2013–2023

Figure 47: Novartis’ SWOT Analysis in ME and AMD, 2013–2023

Figure 48: Regeneron’s SWOT Analysis in ME and AMD, 2013–2023

Figure 49: Bayer’s SWOT Analysis in ME and AMD, 2013–2023

Figure 50: Valeant’s SWOT Analysis in AMD, 2013–2023

Figure 51: Allergan’s SWOT Analysis in ME and AMD, 2013–2023

Figure 52: Alimera Sciences’ SWOT Analysis in ME, 2013–2023

Figure 53: Ampio’s SWOT Analysis in ME, 2013–2023

Figure 54: Ophthotech’s SWOT Analysis in AMD, 2013–2023

Figure 55: Acucela’s SWOT Analysis in AMD, 2013–2023

Figure 56: Ohr Pharmaceutical’s SWOT Analysis in AMD, 2013–2023

Figure 57: Global Sales for ME by Region, 2013–2023

Figure 58: Individual Drug Sales for ME 2013–2023

Figure 59: Global Sales for AMD by Region, 2013–2023

Figure 60: Individual Drug Sales for AMD 2013–2023

Figure 61: Individual Drug Sales for ME in the US, 2013–2023

Figure 62: Individual Drug Sales for AMD in the US, 2013–2023

Figure 63: Individual Drug Sales for ME in France, 2013–2023

Figure 64: Individual Drug Sales for AMD in France, 2013–2023

Figure 65: Individual Drug Sales for ME in Germany, 2013–2023

Figure 66: Individual Drug Sales for AMD in Germany, 2013–2023

Figure 67: Individual Drug Sales for ME in Italy, 2013–2023

Figure 68: Individual Drug Sales for AMD in Italy, 2013–2023

Figure 69: Individual Drug Sales for ME in Spain, 2013–2023

Figure 70: Individual Drug Sales for AMD in Spain, 2013–2023

Figure 71: Individual Drug Sales for ME in the UK, 2013–2023

Figure 72: Individual Drug Sales for AMD in the UK, 2013–2023

Figure 73: Individual Drug Sales for ME in Japan, 2013–2023

Figure 74: Individual Drug Sales for AMD in Japan, 2013–2023

    Pricing

Discounts available for multiple report purchases.

reportstore@globaldata.com
+44 (0) 161 359 5813

Saved reports